- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07693088
Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD)
Intermittent Theta-Burst Stimulation (iTBS) as an add-on to Eye Movement Desensitization and Reprocessing (EMDR) in the Treatment of Post-traumatic Stress Disorder (PTSD): An Open-label Pilot Study
This open-label pilot study will evaluate the feasibility, safety, tolerability, and preliminary clinical outcomes of adding intermittent theta-burst stimulation (iTBS) to Eye Movement Desensitization and Reprocessing (EMDR) therapy in adults with post-traumatic stress disorder (PTSD), who show insufficient improvement after an initial course of EMDR.
Participants will receive weekly EMDR therapy. After seven EMDR sessions, treatment response will be assessed using the Clinical Global Impression-Improvement scale (CGI-I). Participants with insufficient response will receive add-on iTBS targeted to the right dorsolateral prefrontal cortex (DLPFC) for four weeks while continuing EMDR. Feasibility outcomes include adherence, treatment completion, and dropout rates. Clinical outcomes will include clinician-rated and self-reported measures of PTSD symptoms, depressive symptoms, well-being, and adverse events.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Post-traumatic stress disorder (PTSD) is a disabling psychiatric condition characterized by intrusive traumatic memories, avoidance behaviors, negative alterations in cognition and mood, and persistent hyperarousal. Although trauma-focused psychotherapies such as Eye Movement Desensitization and Reprocessing (EMDR) are recommended as first-line treatments, a substantial proportion of patients continue to meet diagnostic criteria for PTSD despite receiving evidence-based psychotherapy.
Intermittent theta-burst stimulation (iTBS), a brief form of repetitive transcranial magnetic stimulation (rTMS), has demonstrated preliminary efficacy in reducing PTSD symptoms and offers practical advantages due to its short treatment duration.
The present study aims to investigate whether iTBS can be feasibly integrated as an adjunctive intervention for patients who do not respond sufficiently to EMDR therapy alone. This is an investigator-initiated, open-label feasibility study conducted within psychiatric services in the Central Denmark Region.
Eligible adults aged 18 to 70 years with a diagnosis of PTSD, who are referred for EMDR treatment, will be enrolled. Participants will receive standardized EMDR therapy consisting of sixteen weekly 90-minute sessions. Following completion of seven EMDR sessions, treatment response will be evaluated using the Clinical Global Impression-Improvement (CGI-I) scale. Participants rated as having insufficient improvement (CGI-I score ≥3) will be offered add-on iTBS.
The iTBS intervention will be delivered to the right DLPFC using a MagPro R30 stimulator and Cool-B70 coil. Treatment will consist of one daily iTBS session administered five days per week over four weeks for a total of 20 sessions. Participants will continue weekly EMDR therapy throughout the iTBS phase and subsequent follow-up period.
The primary objectives are to evaluate the safety, tolerability, and feasibility of the combined EMDR+iTBS intervention. Feasibility outcomes include treatment adherence, treatment completion rates, and dropout rates. Secondary outcomes include adverse events and changes in PTSD symptom severity measured using clinician-rated and self-reported instruments.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Pernille Kølbæk, MD PhD
- Numéro de téléphone: 004561397432
- E-mail: perpet@rm.dk
Sauvegarde des contacts de l'étude
- Nom: Ana Lisa Carmo, Psychiatrist
- Numéro de téléphone: 0045 61155056
- E-mail: ANAMAR@rm.dk
Lieux d'étude
-
-
-
Aarhus N, Danemark
- Aarhus University Hospital
-
Contact:
- Pernille Kølbæk, MD PhD
- Numéro de téléphone: 004561397432
- E-mail: perpet@rm.dk
-
Contact:
- Ana Lisa Carmo, Psychiatrist
- Numéro de téléphone: 0045 61155056
- E-mail: ANAMAR@rm.dk
-
Chercheur principal:
- Ana Lisa Carmo, Psychiatrist
-
Horsens, Danemark
- Regional Psychiatry Horsens
-
Contact:
- Pernille Kølbæk, MD PhD
- Numéro de téléphone: 004561397432
- E-mail: perpet@rm.dk
-
Contact:
- Thea Grønfeldt, Psychiatrist
- Numéro de téléphone: 00457847 9258
- E-mail: theafaer@rm.dk
-
Chercheur principal:
- Pernille Kølbæk, MD PhD
-
Viborg, Danemark
- Regional Psychiatry Central Jutland
-
Contact:
- Pernille Kølbæk, MD PhD
- Numéro de téléphone: 004561397432
- E-mail: perpet@rm.dk
-
Chercheur principal:
- Ana Lisa Carmo, Psychiatrist
-
Contact:
- Ana Lisa Carmo, Psychiatrist
- Numéro de téléphone: 004561155056
- E-mail: ANAMAR@rm.dk
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age 18-70 years
- ICD-10 criteria for PTSD (F43.1)
- A minimum total score of 4 (moderately ill) on the Clinical Global Impression-Severity (CGI-S)
- Likely to be able to complete trial participation (16 weeks) without modifications to psychopharmacological treatment, as per the referring doctor's or psychologist's assessment
- Participants must be able and willing to abstain from alcohol consumption during the iTBS treatment period, as required by the TMS Safety Checklist.
Exclusion Criteria:
- Organic mental disorders (F0)
- Currently fulfills the criteria of Active psychoactive substance use or dependence (F1)
- Schizophrenia, schizotypal and delusional disorders (F2), manic episode (F30), or bipolar affective disorder (F31); iv) Mental retardation (estimated IQ <70, as per the referring doctor's or psychologist's assessment)
- Active suicidality
- Any ongoing involuntary/coercive measures
- Any contraindications listed on the TMS Safety Checklist
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: EMDR with add-on iTBS
Participants receive weekly Eye Movement Desensitization and Reprocessing (EMDR) therapy for up to 16 weeks.
After seven EMDR sessions, treatment response is assessed using the Clinical Global Impression-Improvement scale (CGI-I).
Participants with insufficient response receive adjunctive intermittent theta-burst stimulation (iTBS) to the right dorsolateral prefrontal cortex for 20 sessions over 4 weeks while continuing EMDR.
Participants with sufficient response continue EMDR treatment alone.
|
All enrolled participants begin standardized EMDR treatment.
Participants who show insufficient clinical improvement after seven EMDR sessions receive adjunctive intermittent theta-burst stimulation (iTBS) while continuing EMDR.
Participants who show sufficient improvement continue EMDR alone.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Drop-out
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The primary outcome will be drop-out rates
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Treatment completion rates
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
The second primary outcome will be treatment completion rates (number of iTBS treatments received out of the planned 20 treatments)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Symptom trajectories
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the Clinician Administered PTSD Scale for DSM-5 (CAPS-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the PTSD Checklist for DSM-5 (PCL-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by International Trauma Questionnaire (ITQ)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Symptom trajectories
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Symptom trajectories, as measured by the 6-item self-reported Hamilton Depression Rating Scale (HAM-D6-SR)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Transcranial Magnetic Stimulation Sensory Questionnaire (TMSens_Q)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Adverse event rates
Délai: Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Adverse event rates, measured by means of the Aarhus Side Effects Assessment Scale (ASAQ)
|
Time Frame: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
|
Changes in mental well-being
Délai: From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Mental well-being as measured by the World Health Organization 5-item well-being scale (WHO-5)
|
From initiation of iTBS to completion of the 4-week iTBS treatment period (approximately 4 weeks)
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chaise d'étude: Pernille Kølbæk, Aarhus University Hospital
- Chercheur principal: Ana Lisa Carmo, Aarhus University Hospital
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 2502681
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .